The 7 most recent market catalysts affecting $QTRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
12 Health Care Stocks Moving In Friday's After-Market Session
This filing reports on the after-market trading activity of 12 healthcare stocks, with specific mention of recent Q2 earnings reports as a catalyst for several of these movements. …
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
TD Cowen Maintains Hold on Quanterix, Lowers Price Target to $3
TD Cowen analyst Dan Brennan has lowered the price target for Quanterix (QTRX) from $4 to $3, while maintaining a 'Hold' rating. This action reflects a revised valuation perspectiv…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Quanterix Q2 EPS $(1.04) Misses $(0.40) Estimate, Sales $32.906M Miss $37.462M Estimate
Quanterix (QTRX) announced Q2 earnings that significantly missed analyst expectations on both the top and bottom lines. The reported loss of $(1.04) per share was 160% worse than t…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
CORRECTION: Quanterix Q2 Adj. EPS $(0.47) Misses $(0.46) Estimate, Sales $32.906M Miss $37.462M Estimate
Quanterix (QTRX) announced its Q2 earnings, revealing a miss on both adjusted EPS and revenue estimates. The company reported an adjusted EPS of $(0.47) against an estimate of $(0.…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
Quanterix shares are trading lower after the company reported worse-than-expected Q2 financial results.
This headline indicates a direct corporate catalyst impacting Quanterix (QTRX). Worse-than-expected financial results typically lead to immediate negative share price reactions as …
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 85
Quanterix Lowers FY2026 Sales Guidance from $169.000M-$174.000M to $142.000M-$148.000M vs $169.930M Est
Quanterix announced a substantial reduction in its FY2026 sales outlook, moving from a range of $169M-$174M down to $142M-$148M. This new guidance is significantly below the prior …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
Quanterix Announces Milestones Advancing Clinical Adoption Of Blood-Based Alzheimer's Testing
Quanterix has achieved a significant milestone with Anthem Blue Cross and Blue Shield's decision to cover its blood-based Alzheimer's biomarker testing. This marks a pivotal moment…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.